Rebamipide ophthalmic suspension for the treatment of dry eye syndrome: a critical appraisal

Tomoyuki Kashima1
Hirotaka Itakura1,2
Hideo Akiyama1
Shoji Kishi1
1Department of Ophthalmology, Gunma University, School of Medicine, Maebashi, Gunma, Japan; 2Department of Ophthalmology, Maebashi Red Cross Hospital, Maebashi, Gunma, Japan

Abstract: Rebamipide was initially developed and approved for use in treating gastric ulcers and lesions associated with gastritis. Discovery of its ability to increase gastric mucin led to investigations of its effect on ocular surface mucin and the subsequent development for use in dry eye patients. Investigations have confirmed that rebamipide increases corneal and conjunctival mucin-like substances along with improving corneal and conjunctival injury. Clinically, rebamipide ophthalmic suspensions can effectively treat tear deficiency and mucin-caused corneal epithelial damage, and can restore the microstructure responsible for tear stability. Topical rebamipide has also been shown to be effective in treating other ocular surface disorders such as lagophthalmos, lid wiper epitheliopathy, and persistent corneal erosion. Rebamipide’s ability to modify epithelial cell function, improve tear stability, and suppress inflammation in the absence of any known major side effects suggest that it may be a beneficial first drug of choice for severe dry eye treatment and other ocular surface disorders. This review summarizes the history and development of this innovative dry eye treatment from its initial use as an effective stomach medication to its current use in the treatment of dry eye in Japan.

Keywords: quinolinone derivative, tear deficiency, ocular surface disorder, mucin secretion, Mucosta

History
Rebamipide is a novel quinolinone derivative synthesized and developed by Otsuka Pharmaceutical Company, Limited (Tokyo, Japan) (Figure 1). After its initial discovery, it was used as an agent that promoted the healing of lesions in an experimental rat gastric ulcer model.1,2 Subsequently, in 1990, it was marketed as the Mucosta® tablet (Otsuka Pharmaceutical Company, Limited) for gastric ulcer therapy.3 Rebamipide has been shown to increase gastric endogenous prostaglandin E2 and I2, promote gastric epithelial mucin,1,2 behave as an oxygen free radical scavenger,5,6 and it has other anti-inflammatory actions.7–10 In addition to its use for the gastrointestinal mucosa, the biological effects of rebamipide, which include cytoprotection, wound healing, and anti-inflammatory properties, are known to be universal for a variety of tissues.10 In 1994, gastric mucosal lesions (erosion, hemorrhage, erythema, and edema) associated with gastritis were subsequently added to its indications.11 Since then, it has been widely used as a therapeutic agent for gastritis and gastric ulcers.12 The clinical effectiveness of rebamipide for the treatment of stomatitis;13 pulmonary,14 renal,15 and liver damage;16 colitis;17 and corneal protection18 has been demonstrated by both basic and clinical research.10 This drug also accelerated the healing of experimental gastric ulcers in Mongolian gerbils infected with Helicobacter pylori by improving cell kinetics, reducing apoptosis, and reducing inflammation.19

After discovering that the pharmacological actions of rebamipide included increasing gastric mucus (mucin), its development for use as a dry eye medication began with...
investigations of its effect on the ocular surface mucin.\textsuperscript{1,4,20} In nonclinical studies, it was confirmed that rebamipide increased corneal and conjunctival mucin, and that it increased the conjunctival goblet cells in rabbits.\textsuperscript{21,22} The therapeutic effects of rebamipide are due to its ability to increase corneal and conjunctival mucin-like substances, and to improve corneal and conjunctival injury in vivo.\textsuperscript{18} It is known that rebamipide increases the mucin production in cultured conjunctival goblet cells\textsuperscript{23,24} and in corneal epithelial cells.\textsuperscript{25} These reports additionally indicated that rebamipide increased the secretion of both membrane-associated and secreted-type mucins.

Clinical studies have shown that rebamipide has an improving effect not only on both corneal and conjunctival epithelial damage, but also on subjective symptoms.\textsuperscript{26-28} Based on these results, rebamipide was launched in January 2012 for the treatment of dry eye in Japan (Mucosta ophthalmic suspension unit dose 2%). In this paper, we review the published data and current usage of this innovative drug developed from a preexisting effective stomach medication that essentially has few side effects.

**Mechanism of action for gastric mucosa**

The pharmacological action of rebamipide for gastric mucosal injury is roughly divided into an action related to the protection of the gastric mucosa, which promotes healing of the mucosal injury, and actions related to anti-inflammation and the suppression of free radicals.\textsuperscript{29-32}

A dose-dependent increase in prostaglandin E\textsubscript{2} in the gastric mucosa was observed for rebamipide when it was intraperitoneally administered to rats.\textsuperscript{1} Rebamipide also increased the biosynthetic enzyme activity of the mucosal macromolecular glycoprotein and increased the amount of soluble gastric mucus in rats.\textsuperscript{33}

In terms of the effect on free radicals, rebamipide was shown by electron spin resonance to scavenge hydroxyl radicals, which are very harmful reactive oxygen species that cause cell injury and lipid peroxidation.\textsuperscript{6} In rat neutrophils, rebamipide inhibits superoxide production induced by formyl-methionyl-leucyl-phenylalanine, a membrane receptor stimulator.\textsuperscript{34}

The anti-inflammatory effects of rebamipide include a suppressive action on the infiltration of inflammatory cells into the gastric mucosa and on inflammatory cytokines.\textsuperscript{35} Rebamipide has been shown to inhibit increased interleukin (IL)-8 production induced by H. pylori irritation in cultured gastric cancer cells, which are derived from the gastric mucosa epithelium.\textsuperscript{36} In addition, rebamipide inhibited gastric mucosal injury and myeloperoxidase activity, which serves as an indicator of the infiltration of neutrophils across the gastric mucosa in an indomethacin-induced ulcer model.\textsuperscript{37,38} In an ischemia–reperfusion model, rebamipide inhibited mucosal injury and myeloperoxidase activity in the gastric mucosa.\textsuperscript{38} These effects are related to the concentration of rebamipide in the gastric mucosa, which results from local penetration, as the blood levels and systemic distribution of rebamipide were shown to have little effect on its antioxidative and antineutrophilic activities.\textsuperscript{39}

**Therapeutic effect on gastric ulcers and gastritis**

Rebamipide promoted the healing of a gastric mucosal injury in a rat acetic acid ulcer model.\textsuperscript{2} Recurrence of gastric mucosal injury was shown to be inhibited by the administration of rebamipide in the chronic ulcer model.\textsuperscript{40} When subjective and objective symptoms were examined in human subjects, the improvement rate for patients with marked or moderate improvement was found to be 76%.\textsuperscript{41} Follow-up of cases that were healed after the administration of rebamipide showed that there was a very low recurrence rate of a gastric mucosal injury of 6%.\textsuperscript{42} An investigation of the efficacy of gastritis caused by non-steroidal anti-inflammatory drugs in healthy individuals demonstrated that rebamipide significantly inhibited gastric mucosal injury, erosion, and hemorrhage induced by indomethacin.\textsuperscript{42} Rebamipide has also been shown to contribute to the healing of artificial ulcers induced by endoscopic submucosal dissection for early-stage gastric cancer.\textsuperscript{43,44}

**Corneal and conjunctival mucin**

Mucin on the ocular surface is divided into membrane-associated mucins (MUC1, MUC4, MUC16), which are expressed on the apical surface of the corneal and
conjunctival epithelia, and the secreted-type mucin (MUC5AC), which is produced by conjunctival goblet cells and released into the tear fluid.\textsuperscript{21,45,46} Membrane-associated mucins serve as a barrier by preventing contact with pathogens and foreign substances on the corneal surface. They also play an important role in improving the lubricating property of the corneal surface.\textsuperscript{45,46} The secreted-type mucin contributes to the stability of tear fluid by interacting with the membrane-associated mucin.\textsuperscript{45,46}

With regard to its effect on membrane-associated mucin, rebamipide upregulates the gene expression of MUC1, MUC4, and MUC16, in addition to increasing the expression of protein in the cultured human corneal epithelial cells.\textsuperscript{47} For the secreted-type mucin, the amount of MUC5AC in the tear fluid has been shown to increase in an aqueous-deficient model following the instillation of a rebamipide ophthalmic suspension.\textsuperscript{22} Examination of the total mucin content in a rabbit eye model demonstrated that there was an increase in the corneal and conjunctival mucin content after the administration of a rebamipide ophthalmic solution.\textsuperscript{18}

Rebamipide increased the secretion of both membrane-associated and secreted-type mucins through mucin production in the conjunctival goblet cells, and in the corneal epithelial cells.\textsuperscript{23–25} Although the lack of a complete understanding of ocular mucin expression led to the elimination of mucin deficiency as a definitive entity in dry eye syndrome,\textsuperscript{46} the increase of secretory mucin by rebamipide is related to tear film stability through the enhancement of mucin expression,\textsuperscript{48} which might show another aspect of dry eye syndrome.

Conjunctival goblet cells

Secreted-type mucin is produced and secreted by conjunctival goblet cells. A decrease in the goblet cell number, which has been reported in dry eye patients, is thought to be one of the causes of the onset and exacerbation of dry eye.\textsuperscript{49} Investigations of the effect of rebamipide on the conjunctival goblet cell count using impression cytology found that a rebamipide ophthalmic suspension increased goblet cell count in normal rabbits (Figure 2).\textsuperscript{50}

Corneal and conjunctival epithelial damage

Based on the state of the tear fluid, dry eye is divided into an aqueous-deficient type and an evaporative type.\textsuperscript{51} In aqueous-deficient dry eye, the tear fluid supply from the lacrimal glands decreases and the tear exchange declines, leading to a deterioration in tear quality, such as high osmolality due to Sjögren’s syndrome.\textsuperscript{51} Evaporative dry eye, on the other hand, is caused by decreased tear stability due to various factors. One factor behind decreased tear stability is related to the decreased lubrication of the ocular surface caused by the decreased mucin secretion.\textsuperscript{52}

The effect of a rebamipide ophthalmic suspension on corneal epithelial damage due to aqueous deficiency was investigated using a rat model in which the exorbital lacrimal glands were removed. The findings demonstrated that rebamipide significantly improved the corneal epithelial damage.\textsuperscript{53} Urashima et al\textsuperscript{18} further examined the corneal and conjunctival epithelial damage in N-acetylcysteine-treated rabbit eyes, which causes a mucin deficiency condition on the

![Figure 2](https://www.dovepress.com/)

**Figure 2** Effect of rebamipide on conjunctival goblet cells in rabbit.

**Notes:** (A) Photomicrographs showing PAS staining of filter paper containing PAS-positive cells after 15 days of treatment. Shown on the left is the vehicle-treated group; shown on the right is the 1% rebamipide-treated group. (B) The effects of rebamipide on the number of PAS-positive cells in the conjunctiva. Mean ± standard error (n=7–8). **P**< 0.01 versus vehicle (two-tailed Dunnett test). Reproduced from Urashima H, Okamoto T, Takeji Y, Shinohara H, Fujisawa S. Rebamipide increases the amount of mucin-like substances on the conjunctiva and cornea in the N-acetylcysteine-treated in vivo model. Cornea. 2004;23(6):613–619. Promotional and commercial use of the material in print, digital or mobile device format is prohibited without the permission from the publisher Lippincott Williams & Wilkins. Please contact journalpermissions@lww.com for further information. Copyright © 2004. Wolters Kluwer Health.\textsuperscript{18}

**Abbreviation:** PAS, periodic acid–Schiff reagent.
ocular surface, and demonstrated that rebamipide significantly improved the corneal and conjunctival epithelial damage.

Microvilli on the corneal and conjunctival surface contribute to the stabilization of the tear fluid by serving as a scaffold for the localization of mucin. In dry eye patients, it has been reported that microvilli decrease and become irregular, with the decreases in tear stability occurring in conjunction with the microvilli decrease.\textsuperscript{54} A further study that investigated the effect of rebamipide on corneal and conjunctival microvilli found that rebamipide inhibited the microvilli damage in a N-acetylcysteine-treated rabbit model (Figure 3).\textsuperscript{55}

Overall, these findings suggest that a rebamipide ophthalmic suspension is not only effective for corneal epithelial damage due to tear deficiency and decreased mucin, but also for restoration of the corneal and conjunctival surface microstructure that contribute to the tear stability.

**Inhibition of ocular surface inflammation**

In 2007, the Dry Eye Workshop published a definition of dry eye that stated, “it is accompanied by increased osmolarity of the tear film and inflammation of the ocular surface,” which emphasizes the inflammatory response.\textsuperscript{51} It is thought that the high osmolarity of the tear film is due to decreased tear secretion and increased tear evaporation. Thus, the net result is that the increased osmolarity causes inflammation of the ocular surface.

In a study using cultured human corneal epithelial cells,\textsuperscript{56} rebamipide inhibited IL-6 and IL-8 production induced by tumor necrosis factor alpha (TNF-\(\alpha\)). These findings suggested that the mechanism responsible for the inhibition was the inhibition of NF\(\kappa\)B activation. The tight junctions that exist between the corneal epithelial cells serve an important function as a barrier for deeper corneal tissue. A further study used electrical resistance and the expression of ZO-1, which is a tight junction protein, as indicators of the effect of rebamipide on the inflammatory cytokine-caused damage to tight junctions.\textsuperscript{51} The study results demonstrated that rebamipide had an inhibitory effect on TNF-\(\alpha\)-induced decreased electrical resistance, in addition to having an inhibitory effect on decreased ZO-1 (occluding) expression. Furthermore, this study also found that a rebamipide ophthalmic suspension reversed the decrease in ZO-1 expression in the corneal epithelium in a rat dry eye model in vivo.\textsuperscript{53}

Recently, Ueta et al\textsuperscript{57} reported that rebamipide significantly attenuated the production of inflammatory cytokines and downregulated the messenger ribonucleic acid level of these cytokines. This study showed that the infiltration of eosinophils was suppressed in a dose-dependent manner. Based on Rebamipide’s ability to modify epithelial cell functions, the authors suggested that this may open new strategies for treating human ocular surface inflammation, including allergic conjunctivitis and dry eye diseases.\textsuperscript{57}


**Rebamipide for clinical application**

It has not been long since the rebamipide ophthalmic suspension was launched; however, several reports on its clinical application have been published. The study design and patient numbers adopted in those papers are different, and those characteristics were summarized in Table 1. We will introduce these reports in this section.

**Rebamipide for dry eye syndrome**

Randomized, double-masked, placebo-controlled, multicenter, and parallel-group clinical trials for rebamipide treatment of the human ocular surface are currently being conducted. Kinoshita et al reported improvements of the fluorescein corneal staining score, lissamine green conjunctival staining score, and tear film break-up time score during their investigation of the rebamipide dose response, although they also found no significant difference for Schirmer’s test values between the rebamipide and placebo groups. The authors reported that dry eye-related ocular symptom scores and the patients’ overall treatment impression showed significant improvements in the 1% and 2% rebamipide groups. They confirmed the efficacy findings of their Phase II study results and demonstrated the superiority of 2% rebamipide to the 0.1% sodium hyaluronate.

Additionally, in a subsequent Phase III study that compared 2% rebamipide with 0.1% sodium hyaluronate, Kinoshita et al demonstrated that there were no adverse events with either 2% rebamipide or 0.1% sodium hyaluronate similar to those associated with the benzalkonium chloride preservative. However, the authors considered the advantage of the rebamipide ophthalmic suspension, in that it does not contain preservatives, which can cause destabilization of the tear film, disruption of the corneal epithelium, a decrease of the density of the goblet cells, conjunctival squamous metaplasia with apoptosis, and damage to the deeper ocular tissues. The most frequently observed adverse event for the rebamipide ophthalmic suspension in the Kinoshita et al Phase III study was dysgeusia (bitter taste); however, this was only observed in 9.7% of the 2% rebamipide group.

There is a poor correlation between the symptoms and signs of dry eye, as only 57% of symptomatic patients have been found to exhibit objective signs of dry eye. Thus, an assessment of efficacy using subjective measures (symptoms), as well as objective measures (signs), is particularly important to perform in patients with dry eye.

Koh et al reported finding significant increases in the tear film break-up time, and there were significant upward curves from the baseline in terms of the total corneal higher-order aberrations, coma-like aberrations, and spherical-like aberrations after the application of rebamipide (Figure 4). In addition, their study demonstrated that rebamipide improved tear stability, possibly leading to improved optical quality. Therefore, an assessment of optical quality and the evaluation of the mucin level can provide supportive evidence regarding the importance of mucin for the quality of vision in patients with dry eye. The authors reported in another study that a significant increase in higher-order aberrations and forward light scatter occurred 1 minute after the instillation of rebamipide suspension, which returned to the preinstillation level.

**Table 1** Comparison of the clinical reports introduced in this review

<table>
<thead>
<tr>
<th>Author</th>
<th>Year</th>
<th>Study design</th>
<th>Number of patients</th>
<th>Target disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kinoshita et al</td>
<td>2012</td>
<td>Randomized study</td>
<td>308</td>
<td>Dry eye patients</td>
</tr>
<tr>
<td>Kinoshita et al</td>
<td>2013</td>
<td>Randomized study</td>
<td>188</td>
<td>Dry eye patients</td>
</tr>
<tr>
<td>Koh et al</td>
<td>2013</td>
<td>Case series</td>
<td>16</td>
<td>Dry eye patients</td>
</tr>
<tr>
<td>Takahashi et al</td>
<td>2014</td>
<td>Case series</td>
<td>7</td>
<td>Superior limbic keratoconjunctivitis</td>
</tr>
<tr>
<td>Itakura et al</td>
<td>2013</td>
<td>Case series</td>
<td>2</td>
<td>Mild lagophthalmos</td>
</tr>
<tr>
<td>Itakura et al</td>
<td>2013</td>
<td>Case series</td>
<td>1</td>
<td>Lid wiper epitheliopathy</td>
</tr>
<tr>
<td>Kashima et al</td>
<td>2012</td>
<td>Case report</td>
<td></td>
<td>Persistent corneal erosion</td>
</tr>
</tbody>
</table>
Rebamipide for other ocular surface disorders

As we have previously discussed, the administration of topical rebamipide improves the ocular surface in dry eye. However, several previous studies have found that topical rebamipide was not only effective for dry eye patients, but also for other ocular surface disorders with or without dry eye, such as superficial limbic keratopathy (SLK), lagophthalmos, lid wiper epitheliopathy, and persistent corneal erosion.62–65

Takahashi et al62 reported that thyroid eye disease patients with SLK who received topical rebamipide all showed improvements in SLK, which showed the complete disappearance of SLK after treatment in 84.8% of patients. The authors concluded that topical rebamipide may be a first-line treatment in such patients.62

One study64 examined seven eyes in seven cases with mild lagophthalmos (three cases after eyelid surgery, two cases of incomplete facial nerve palsy, and two cases of senile ectropion); the fluorescein corneal staining score and tear break-up time were significantly improved, and the scores for the ocular symptoms, such as eye pain, dryness, blurred vision, and foreign body sensations, also significantly improved. These results were similar to those of the clinical studies conducted with the dry eye patients (Figure 5).58,59

In another study, topical rebamipide was also shown to be effective for corneal and conjunctival disorders in lid wiper epitheliopathy.63 Although sodium hyaluronate and diquafo-sol are known to suppress inflammation, this study found that the anti-inflammatory effect of rebamipide was greater than that of either of the drugs. Based on these findings, rebamipide eye drops were suggested as the first choice of treatment for patients with lid wiper epitheliopathy.63 In another case report,65 rebamipide was administered to Sjögren’s syndrome patients who had erosion in the inferior cornea after surgical punctual occlusion. After application, the corneal erosion gradually improved and completely disappeared at 4 weeks after administration, even though other existing drugs had not been able to previously treat the erosion.

Conclusion

The rebamipide ophthalmic suspension was launched in January 2012 in Japan. Two years after this launch, published data have shown that this drug has been advantageous for the treatment of dry eye, as compared to other existing drugs currently being used, including lubricants. From our
clinical experience of using this drug, the improvement of ocular surface conditions after its application is remarkable for the patients, especially in severe conditions. Overall, these findings confirm our belief that topical rebamipide may become the first drug of choice for some cases of dry eye syndrome. Moreover, we believe that this drug has a great potential to change the framework of treatment for ocular surface disorders in the future.

Disclosure
The authors report no conflicts of interest in this work.

References


